Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
dalazatide · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 30ug dalazatide | EXPERIMENTAL | 12 subjects, 10 given active agent and 2 given placebo by subcutaneous injection twice weekly for 4 weeks. |
| 60ug dalazatide | EXPERIMENTAL | 12 subjects, 10 given active agent and 2 given placebo by subcutaneous injection twice weekly for 4 weeks. |
| dalazatide 5ug | EXPERIMENTAL | 8 subjects, 6 given active agent and 2 given placebo |
| dalazatide 15ug | EXPERIMENTAL | 8 subjects, 6 given active agent and 2 given placebo |
| dalazatide 30ug | EXPERIMENTAL | 8 subjects, 6 given active agent and 2 given placebo |
| dalazatide 60ug | EXPERIMENTAL | 8 subjects, 6 given active agent and 2 given placebo |
| Name | Type | Description |
|---|---|---|
| dalazatide | DRUG | Subcutaneous injection twice per week for a total of 9 doses, followed by four weeks of follow-up. |
| placebo | DRUG | placebo, Subcutaneous injection twice per week for a total of 9 doses |
Inclusion Criteria: 1. Adult male and female subjects, ages 18-65; 2. Active plaque psoriasis with ≥3% BSA involved; 3. An adequate number of vulgar psoriatic plaques of at least 2 cm X 2 cm with Target Lesion Investigator Global Assessment scores \>3, that are not located on the face, scalp, groin...